DNA Jan 2025 1.000 put
| Previous Close | 0.8000 |
| Open | 0.7900 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 1.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 0.7900 - 0.8000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 7.86k |
PR NewswireGinkgo Regains Compliance with NYSE Minimum Bid Price Requirement
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced that it had received a letter from the New York Stock Exchange ("NYSE") on September 3, 2024 stating that because Ginkgo's Class A common stock had a closing bid price at or above $1.00 on the last day of August and the Company's 30-day trading average closed above $1.00, Ginkgo had regained compliance with Section 802.01C of the NYSE
- PR Newswire
Ginkgo Bioworks Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Chief Financial Officer, Mark Dmytruk, is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6 at 11:30 a.m. ET.
Simply Wall St.Ginkgo Bioworks Holdings Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Ginkgo Bioworks Holdings ( NYSE:DNA ) Second Quarter 2024 Results Key Financial Results Revenue: US$56.2m (down 30...
